# OnCo record nct05286957 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct05286957/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct05286957", "NCT05286957" ;
  schema:name "MRD-guided Adjuvant Tislelizumab and Chemotherapy in Resected Stage IIA-IIIB NSCLC"@en ;
  schema:alternateName "Seagull"@en ;
  schema:description "A phase 2 trial in lung cancer, run by The First Affiliated Hospital of Zhengzhou University, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct05286957/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05286957> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest", "lung-deep-dive" ;
  onco:phase "2" ;
  onco:cancers <https://onco.cc/cancers/resectable-nsclc/> ;
  onco:technologies <https://onco.cc/technologies/mrd-testing/> ;
  onco:companies <https://onco.cc/companies/beone/> .